Development of NLCs for Topical ATRAs Applications

Abstract:

NLCs are second generation of lipid nanoparticles which have many advantages that make them interesting for topical drugs delivery systems. All-trans retinoic acids (ATRAs) are highly lipophilic and instable in the presence of air, light and heat. In this study, 0.3% ATRAs loaded NLCs were developed by de novo emulsifications, then were reduced to nanometer range by ultrasonicator. The characterizations of NLCs i.e. size and zeta potential were examined. NLCs with different solid:liquid lipids ratios (2:1, 1:1 and 1:2), were formulated in order to maximize the skin permeation. The results demonstrate the sizes of NLCs were in nanometer ranges with negative zeta potential. Moreover the results showed that the amount of solid lipids in the formulation affected the skin permeation. The highest ATRAs permeations though shed snake skin could be achieved from the NLCs which lipid matrixs were composed of 2:1 solid:liquid lipids ratios.

• Periodical: Advanced Materials Research (Volume 506)
• Pages: 162-165
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.506.162
• Online since: April 2012
• Authors: P. Chareanputtakhun, Theerasak Rojanarata, Praneet Opanasopit, Tanasait Ngawhirunpat
• Keywords: All-Trans Retinoic Acid, ATRAs, Nanostructure Lipid Carriers, NLCs, TDDS, Topical Drug Delivery Systems

References

[1] H. Gollnick, W. Cunliffe, D. Berson, B. Dreno, A. Finlay, J.J. Leyden, A.R. Shalita, D Thiboutot: J. Am. Acad. Dermatol. Vol. 49 (2003), p.17.

DOI: 10.1067/mjd.2003.618

[2] V. Masini, F. Bonte, A. Meybeck, J. Wepierre: J. Pharm. Sci. Vol. 82 (1993), p.17.

[3] M. Manconi, D. Valenti, C. Sinico, F. Lai, G. Loy, A.M. Fadda: Int. J. Pharm. Vol. 260 (2003), p.261.

[4] R.Y. Anadolu, T. Sen, N.A. TarimciBirol, C. Erdem: J. Eur. Acad. Dermatol. Venerol. Vol. 18 (2004), p.416.

[5] A. S. Kumar, A.D. Abhijit: Int. J. Pharm. Vol. 345 (2007), p.163.

[6] R.H. Muller, R.D. Petersen, A. Hommoss, J. Pardeike: Adv. Drug Delivery Rev. Vol. 59 (2007), p.522.

[7] V.B. Junyaprasert, V. Teeranachaideekula, E.B. Soutoc, P. Boonmed, R.H. Muller: Int J Pharm. Vol. 377 (2009), p.207.